Metabonomics and the Gut Microbiome Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease
NS Ding, JAK McDonald, A Perdones-Montero, Douglas N Rees, SO Adegbola, R Misra, P Hendy, L Penez, JR Marchesi, E Holmes, MH Sarafian, AL Hart
Journal of Crohn's and Colitis | OXFORD UNIV PRESS | Published : 2020
BACKGROUND AND AIMS: Anti-tumour necrosis factor [anti-TNF] therapy is indicated for treatment of moderate to severe inflammatory bowel disease [IBD], but has a primary non-response rate of around 30%. We aim to use metabonomic and metataxonomic profiling to identify predictive biomarkers of anti-TNF response in Crohn's disease. METHODS: Patients with luminal Crohn's disease, commencing anti-TNF therapy, were recruited with urine, faeces, and serum samples being collected at baseline and 3-monthly. Primary response was defined according to a combination of clinical and objective markers of inflammation. Samples were measured using three UPLC-MS assays: lipid, bile acid, and Hydrophillic Inte..View full abstract
This work was supported by a European Crohn's and Colitis Organisation grant and infrastructure support was provided by the National Institute for Health Research [NIHR] Imperial Biomedical Research Centre [BRC] within the Gut Health Theme.